**ABSTRACT.** Platelet function hyper-activity has been reported in *Dirofilaria immitis* (heartworm, HW)-infected dogs. Although the mechanism of increased platelet hyper-activity has not yet been elucidated, it is suggested to be mediated by unknown factors, which may be related to adult HW components. This study aims to determine whether adult male HW whole body extract induces canine platelet aggregation *in vitro*. The results indicate that HW extract caused an aggregation of canine platelets in a concentration-dependent manner. This aggregation ability of the HW extract was not mediated by the adenosine diphosphate receptor. In addition, the mechanisms of aggregation did not require cyclooxygenase-dependent pathways, and the aggregating activity of substances contained in the HW extract was heat stable; therefore, the active substances may be different from collagen. Furthermore, the platelet aggregating activity remained within the molecular weight (MW) ≥ 100,000 fraction obtained by ultrafiltrating the HW extract. In contrast, the MW < 100,000 fraction also had a platelet aggregation ability, but the aggregation pattern was reversible and the maximum extent decreased, compared with the MW ≥ 100,000 fraction response. Our experiments have been conducted using a whole body extract from adult HWs to determine with certainty the aggregating activity of HW elements on canine platelets. More studies are necessary to evaluate the effects of the metabolic products released from live adult worms in pulmonary arteries and the symbiont bacterium *Wolbachia*-derived antigens on canine platelet aggregation.

**KEY WORDS:** *Dirofilaria immitis*, dog, heartworm extract, platelet aggregation
metabolic products of HWs and the substances released into the blood stream due to the death of HWs, because HW infection could exist in two conditions in the infected dogs: (1) a condition in which only live adult HWs reside in the pulmonary arteries; (2) a condition in which the live adult HWs coexist with some dead worms in the pulmonary arteries. Thus, this study aimed at determining whether HW whole body extract induces canine platelet aggregation in vitro.

**MATERIALS AND METHODS**

**Preparation of the HW extract**

The HW extract was prepared from adult male HWs, which did not comprise microfilariae components, obtained from HW-infected dogs. The collected HWs were washed several times with physiologic saline (0.9% sterilized NaCl solution) and kept at −30°C until used for the preparation. Five frozen uninjured HWs were thawed and cut into small fragments using scissors. They were then mashed with a mortar and sonicated at 30 sec × 5 times in 1 ml of veronal buffer (5.88 g/l sodium diethylbarbiturate and 7.34 g/l sodium chloride, pH 7.4). The worm suspension was centrifuged at 10,000 × g for 60 min, and the supernatant solution was collected. All steps were conducted at 4°C. The stock solution, of which 1 ml was equivalent to the volume extracted from 5 HWs, was stored in units of 0.1 ml at −80°C until used for the platelet aggregation assay (see below).

Since cyclooxygenase (COX) products, such as prostaglandins (PGs) and TXs, might be produced during the HW extract preparation [7], HWs were treated with 10 µM indomethacin, a COX inhibitor, in the veronal buffer at room temperature for 30 min [18] before preparation of the HW extracts in the same way as above. The indomethacin-treated HW extracts were stored at −80°C until they were compared with the non-treated HW extracts.

**Preparation of canine platelets**

Blood samples were collected from 12 healthy, HW-free beagles (6 sexually intact females and 6 sexually intact males, aged approximately 3–10 years, weighing 7.6–12.6 kg), who had not received any medications during the preceding 2 weeks, and mixed in a one-to-one volume of 3.2% sodium citrate solution. Platelet-rich plasma (PRP) was obtained by centrifugation at 100 × g for 5 min at room temperature. After collecting the PRP, the remaining samples were recentrifuged at 800 × g for 10 min at room temperature, and the supernatant was collected as platelet-poor plasma (PPP). Platelet counts in the PRP were determined by the use of an automated hematology analyzer (PCE-170, ERMA, Tokyo, Japan) and adjusted to a concentration of 2–3 × 10^8 platelets/ml by the addition of autologous PPP. The PRP was allowed to sit undisturbed at room temperature until used for aggregation studies. The study was performed in compliance with the Gifu University Guidelines for Animal Experimentation.

**Determination of platelet aggregation**

Platelet aggregation was determined by a standard turbidimetric method [10, 22, 24] using an aggregometer (PAT-2M, Niko Bioscience, Tokyo, Japan). Platelet aggregation was expressed as an increase in light transmission, the levels of which were calibrated as 0% for PRP and 100% for PPP. PRP (2–3 × 10^8 platelets/ml, 0.2 ml) in a cuvette was pre-incubated at 37°C for 3 min under continuous stirring at 1,000 rpm. After pre-incubation, platelet aggregation was initiated by the addition of appropriate concentrations of HW extract (22 µl of stock solution finally diluted 10 times by volume), ADP (final concentration 40 µM) or collagen (final concentration 2.5 µg/ml) and monitored for 5 min. The aggregation was expressed as the percent of maximal aggregation. This value was calculated by the following formula:

\[ \text{aggregation value for the sample/aggregation value obtained for 40 \, \mu M \, ADP} \times 100 \% \]

Effect of a heat treatment on platelet aggregation induced by a HW extract

To determine whether the platelet aggregating activity present in the HW extract was stable, the influence of a heat treatment on the HW extract and platelet aggregation was studied. A heat-treated HW extract was prepared as follows. The stock solution (non-treated HW extract) was incubated at 100°C for 10 min and centrifuged again at 10,000 × g at 4°C for 60 min. The supernatant solution was collected and kept as a heat-treated HW extract at −80°C until used for the preparation. As a control, platelet aggregation by collagen (final concentration of 2.5 µg/ml) with or without a heat-treatment was observed.

Involvement of COX-dependent pathways and the ADP receptor on canine platelet aggregation induced by a HW extract

To examine the involvement of COX-dependent pathways and the ADP receptor on canine platelet aggregation induced by a HW extract, the following tests were conducted. Firstly, after the pre-incubation of indomethacin (300 µM) [11] at 37°C for 3 min, platelet aggregation was initiated by the addition of 22 µl of HW extract stock solution or 10 µg/ml (final concentration) of collagen (control) and monitored for 5 min. Next, ATP, an antagonist of P2Y (ADP) receptor, was pre-incubated with PRP at a final concentration of 1 mM for 3 min [9]. Then, 22 µl of the HW extract or 40 µM ADP (control) were added to the pre-mixed PRP.

Ultrafiltration of the HW extract

To examine the involvement of COX-dependent pathways and the ADP receptor on canine platelet aggregation induced by a HW extract, the following tests were conducted. Firstly, after the pre-incubation of indomethacin (300 µM) [11] at 37°C for 3 min, platelet aggregation was initiated by the addition of 22 µl of HW extract stock solution or 10 µg/ml (final concentration) of collagen (control) and monitored for 5 min. Next, ATP, an antagonist of P2Y (ADP) receptor, was pre-incubated with PRP at a final concentration of 1 mM for 3 min [9]. Then, 22 µl of the HW extract or 40 µM ADP (control) were added to the pre-mixed PRP.
Statistical analysis

Each experiment was repeated at least 3 times. Results are expressed as means ± SD with the number of observations (n). Pairwise comparisons were made using a Student’s t-test where appropriate. A value of $P<0.05$ was considered significant.

RESULTS

**HW extract causes canine platelet aggregation**

As shown in Fig. 1A, the HW extract was a potent inducer of irreversible platelet aggregation in citrated canine PRP. The aggregation response was observed immediately after the addition of the HW extract without the appearance of a lag phase (“shape change” period) and reached a maximum aggregation 5 min after the administration of the extract. All PRP samples collected from 11 healthy dogs also induced a similar aggregation of platelets. The maximum amplitude of platelet aggregation was 61.15 ± 16.58% (11).

When indomethacin-treated HW extracts were similarly assayed, they each elicited a substantially similar effect to that of the corresponding extract without an indomethacin treatment (57.61 ± 20.77% (3) vs. 61.15 ± 16.58%, not significant).

Then, having diluted the extract with the veronal buffer to make serial dilutions of 2, 10, 100 and 500 times, the maximum amplitudes of the platelet responses were decreased in a dilution ratio-dependent manner (Fig. 1A). Moreover, the aggregation proceeded more slowly, especially for the 100 times and 500 times diluted extracts.
Effect of a heat treatment on platelet aggregation induced by a HW extract

As shown in Fig. 1B, a heat-treated HW extract (100°C for 10 min) showed a similar activity to the non-treated HW extract. In contrast, heat-treated collagen completely lost the ability to induce platelet aggregation. These results indicate that the factors in the extract inducing platelet aggregation are heat-resistant and are other than collagen.

Involvement of COX-dependent pathways and the ADP receptor on canine platelet aggregation induced by a HW extract

Platelets are activated in either a COX-dependent or COX-independent pathway [3, 24]. To determine whether COX-dependent pathways may be involved in HW extract-induced platelet activation, we used the selective COX inhibitor, indomethacin [11, 18]. Canine PRP pretreated with indomethacin had no reduction in aggregation compared to full inhibition of aggregation in collagen (Fig. 1C). This suggests that COX-dependent pathways are not required for the activation of platelets induced by a HW extract, presumably through the feedback action of TXA2.

ADP plays a pivotal role in hemostasis and thrombosis as an important physiological agonist which activates platelets through ADP receptors and induces platelet aggregation [19]. The involvement of P2Y (ADP) receptor on platelet aggregation induced by a HW extract was examined. Thus, ATP, an antagonist of P2Y receptor, was pre-treated with PRP at a final concentration of 1 mM. As shown in Fig. 1D, ATP inhibited platelet aggregation induced by ADP, but not platelet aggregation induced by a HW extract. These results indicate that platelet aggregation induced by a HW extract was ADP receptor-independent.

Separation of the soluble HW-derived mediators involved in platelet aggregation

When the HW extract was separated with a MW cutoff of 100,000, the MW≥100,000 fraction induced platelet aggregation (Fig. 2A). The pattern and the maximum extent of the aggregations were similar to those induced by the non-separated extract (Figs. 1A and 2A). Although the MW <100,000 fraction also induced platelet aggregation, the aggregation pattern and the maximum extent were variable among the 3 dogs that were tested (Fig. 2B). Namely, the aggregation pattern was reversible, which was not observed with the non-separated PRP or with the MW≥100,000 fraction, and the maximum extent was decreased (Fig. 2B).

DISCUSSION

Our results showed that the whole body extract obtained from adult HWs caused an aggregation of canine platelets in a concentration-dependent manner. The platelet aggregating activities remained in an indomethacin-treated HW extract, indicating that the active substances differed from COX products that might be produced during HW extract preparation. This platelet aggregation ability of the HW extract was not mediated by the ADP receptor. The mechanisms of platelet aggregation did not require COX-dependent pathways, and the aggregating activity of substances contained in the HW extract was heat stable; therefore, the active substances may be different from collagen [3]. Furthermore, the platelet aggregating activity remained in the MW≥100,000 fraction. Conversely, the MW<100,000 fraction also had platelet aggregating ability, but the aggregation pattern was reversible and the maximum extent was decreased compared with the MW≥100,000 fraction response. Thus, platelet aggregating substances in the HW extract might form homo- or hetero-polymers, and the macromolecular forms are stable. There is also a possibility that the HW extract contains more than one substance that induces platelet aggregation.

We used a HW extract, of which 1 ml was equivalent to the volume extracted from 5 HWs, that was finally diluted 10 times by volume. Although the platelet aggregating activities of the HW extract decreased gradually as its dilution with the buffer increased, it should be noted that the activity remained in the extract that was diluted 500 times by volume (finally diluted 5,000 times). If the platelet aggregating substances of HWs might be released into the circulation, these substances can diffuse and are diluted.
HEARTWORM EXTRACT AGGREGATES PLATELET

a result, the diluted active substances in the circulation weakly stimulate platelets. When the stimulus is weak, platelets become hyper-responsive but do not aggregate. It can be said that the weak stimulation of the diluted active substances in the circulation resulted in the enhanced platelet reactivity/sensitivity to ADP and collagen in vitro, as previously reported by Boudreaux et al. [2]. In addition, it is possible that a more continuous or strong stimulation due to the death of a few worms causes degranulation of the platelets, resulting in the release of TXA₂, serotonin and ADP. Accordingly, the production of thrombin and the subsequent formation of thrombosis occur, resulting in a decrease in plasma AT activity [1] and an increase in the plasma D-dimer concentration [4, 5].

Our experiments have been performed using a whole body extract from adult HWs to determine with certainty the aggregating activity of HW elements on canine platelets. Although these results contribute to our understanding of the effects on canine platelets caused by the simultaneous death of a massive number of worms, either naturally or induced by a filarcide treatment, we cannot examine the effects of the metabolic products released from live adult worms in pulmonary arteries. In addition, the whole body extract prepared from adult male HWs did not comprise the microfilariae components, but the molecules of Wolbachia [16]. The symbiotic bacterium Wolbachia is present in the HW body and has been implicated in the modulation of the host inflammatory and immune responses during infection [23]. Therefore, the results observed in this study might also be the effects of Wolbachia components on canine platelets.

In contrast to our findings in HWs, the microfilariae of Brugia malayi, a human filarial parasite, inhibited platelet aggregation [8, 12]. They showed that the microfilariae of B. malayi utilized both exogenous and endogenous arachidonic acid to generate COX-derived, anti-aggregatory eicosanoids, such as prostacyclin and PGE₂ [13]. To our knowledge, there have been no reports on the inhibition of platelet aggregation induced by the extract of adult worms or the microfilariae of HWs. A further study of whether the HW extract might inhibit platelet aggregation of the host should be conducted.

In conclusion, we have demonstrated for the first time that the whole body extract from adult male HWs induces canine platelet aggregation in vitro. More studies are necessary to determine whether the metabolic products, such as excretory/secretory products, excreted by live adult HWs or the Wolbachia components might cause platelet aggregation, respectively. Further studies are needed to elucidate the signaling mechanism involved in HW extract-induced platelet aggregation.

REFERENCES

1. Boudreaux, M. K. and Dillon, A. R. 1991. Platelet function, antithrombin-III activity, and fibrinogen concentration in heartworm-infected and heartworm-negative dogs treated with thiacytarsamide. Am. J. Vet. Res. 52: 1986–1991. [Medline]

2. Boudreaux, M. K., Dillon, A. R. and Spano, J. S. 1989. Enhanced platelet reactivity in heartworm-infected dogs. Am. J. Vet. Res. 50: 1544–1547. [Medline]

3. Brainard, B. M., Meredith, C. P., Callan, M. B., Budsberg, S. C., Shofer, F. S., Driessen, B. and Otto, C. M. 2007. Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. Am. J. Vet. Res. 68: 251–257. [Medline] [CrossRef]

4. Carretón, E., Corbera, J. A., Juste, M. C., Morchón, R., Simón, F. and Montoya-Alonso, J. A. 2011. Dirofilaria immitis infection in dogs: cardiopulmonary biomarker levels. Vet. Parasitol. 176: 313–316. [Medline] [CrossRef]

5. Carretón, E., González-Miguel, J., Montoya-Alonso, J. A., Morchón, R., Simón, F., Passeri, B., Cantoni, A. M. and Kramer, L. 2013. D-dimer deposits in lungs and kidneys suggest its use as a marker in the clinical workup of dogs with heartworm (Dirofilaria immitis) disease. Vet. Parasitol. 191: 182–186. [Medline] [CrossRef]

6. Clemons, R. M., Yamaguchi, R. A., Schaub, R. G., Fleming, J., Dorsey-Lee, M. R. and McDonald, T. L. 1986. Interaction between canine platelets and adult heartworms: platelet recognition of heartworm surfaces. Am. J. Vet. Res. 47: 322–325. [Medline]

7. Derksen, A. and Cohen, P. 1975. Patterns of fatty acid release from endogenous substrates by human platelet homogenates and membranes. J. Biol. Chem. 250: 9342–9347. [Medline]

8. Foster, C. B., Flanigan, T. P., Kazura, J. W., Dumenco, L. L. and Ratnof, O. D. 1991. Inhibition of the activation of Hageman factor (factor XII) and of platelet aggregation by extracts of Brugia malayi microfilariae. J. Lab. Clin. Med. 117: 344–352. [Medline]

9. Kauffenstein, G., Hechler, B., Cazenave, J. P. and Gachet, C. 2004. Adenine triphosphate nucleotides are antagonists at the P2Y₁₂ receptor. J. Thromb. Haemost. 2: 1980–1988. [Medline] [CrossRef]

10. Kurata, M., Ishizuka, N., Matsuzawa, M., Haruta, K. and Takeda, K. 1987. The effect of thromboxane A₂ synthesis inhibitors on platelet aggregation in whole blood. Thromb. Res. 46: 555–566. [Medline] [CrossRef]

11. Liu, L. X. and Weller, P. F. 1992. Intravascular filarial parasites inhibit platelet aggregation. Role of parasite-derived prostanooids. J. Clin. Invest. 89: 1113–1120. [Medline] [CrossRef]

12. Liu, L. X., Serhan, C. N. and Weller, P. F. 1999. Intravascular filarial parasites elaborate cyclooxygenase-derived eicosanoids. J. Exp. Med. 191: 993–996. [Medline] [CrossRef]

13. McCaul, J. W., Genchi, C., Kramer, L. H., Guerrero, J. and Venco, L. 2008. Heartworm disease in animals and humans. Adv. Parasitol. 66: 193–285. [Medline] [CrossRef]

14. McConnell, L. A. and Leid, R. W. 1983. Aggregation of equine platelets by Onchocerca cervicalis collagen. Am. J. Pathol. 110: 290–296. [Medline]

15. Morchón, R., Rodríguez-Barbero, A., Velasco, S., López-Belmonte, J. and Simón, F. 2008. Vascular endothelial cell activation by adult Dirofilaria immitis antigens. Parasitol. Int. 57: 441–446. [Medline] [CrossRef]

16. Morchón, R., Juste, M. C., Montoya-Alonso, J. A., González-Miguel, J., Rodríguez-Barbero, A. and Simón, F. 2009. Are microfilariae related to the production of eicosanoids in dogs naturally infected with Dirofilaria immitis? Rev. Iber. Parasitol. 1: 21–24.

17. Muramatsu, M., Iwama, Y., Shimizu, K., Asano, H., Toki, Y., Miyazaki, Y., Okumura, K., Hashimoto, H. and Ito, T. 1992. Hypoxia-elicited...
contraction of aorta and coronary artery via removal of endothelium-derived nitric oxide. Am. J. Physiol. 263: H1339–H1347. [Medline]

19. Murugappa, S. and Kunapuli, S. P. 2006. The role of ADP receptors in platelet function. Front. Biosci. 11: 1977–1986. [Medline] [CrossRef]

20. Schaub, R. G., Keith, J. C. Jr., Simmons, C. A. and Rawlings, C. A. 1985. Smooth muscle proliferation in chronically injured canine pulmonary arteries is reduced by a potent platelet aggregation inhibitor U-53,059. Thromb. Haemost. 53: 351–355. [Medline]

21. Simón, F., Siles-Lucas, M., Morchón, R., González-Miguel, J., Mellado, I., Carretón, E. and Montoya-Alonso, J. A. 2012. Human and animal dirofilariasis: the emergence of a zoonotic mosaic. Clin. Microbiol. Rev. 25: 507–544. [Medline] [CrossRef]

22. Sudo, T., Ito, H. and Kimura, Y. 2003. Characterization of platelet aggregation in whole blood of laboratory animals by a screen filtration pressure method. Platelets 14: 239–246. [Medline] [CrossRef]

23. Taylor, M. J., Cross, H. F., Ford, L., Makunde, W. H., Prasad, G. B. and Bilo, K. 2001. Wolbachia bacteria in filarial immunity and disease. Parasite Immunol. 23: 401–409. [Medline] [CrossRef]

24. Wiinberg, B., Jessen, L. R., Tarnow, I. and Kristensen, A. T. 2012. Diagnosis and treatment of platelet hyperactivity in relation to thrombosis in dogs and cats. J. Vet. Emerg. Crit. Care (San Antonio) 22: 42–58. [Medline] [CrossRef]